Literature DB >> 33762211

Five-year resistance trends in pathogens causing healthcare-associated infections at a multi-hospital healthcare system in Saudi Arabia, 2015-2019.

Abbas Al Mutair1, Saad Alhumaid2, Zainab Al Alawi3, Abdul Rehman Z Zaidi4, Ahmed J Alzahrani5, Jaffar Al-Tawfiq6, Haifa Al-Shammari7, Ali Rabaan8, Osamah Khojah9, Awad Al-Omari4.   

Abstract

OBJECTIVES: Awareness of antimicrobial resistance (AMR) patterns in a given healthcare setting is important to inform the selection of appropriate antimicrobial therapy to reduce the further rise and spread of AMR as well as the rate of healthcare-associated infections (HAIs) and multidrug-resistant (MDR) organisms. We aimed to describe resistance patterns to several antimicrobial agents in pathogens causing HAIs isolated from patients using data gathered at three private tertiary-care hospitals in Saudi Arabia.
METHODS: Data on trends in AMR among bacteria causing HAIs and MDR events in children and adults at three private hospitals were collected retrospectively (2015-2019) using surveillance data.
RESULTS: Over the 5-year period, 29 393 pathogens caused 17 539 HAIs in 15 259 patients. Approximately 57.3% of patients were female and the mean age was 38.4 ± 16.8 years (81.4% adults, 18.6% children). Gram-negative pathogens were four times more likely to cause HAIs compared with Gram-positive bacteria (79.3% vs. 20.7%). Ranking of causative pathogens in decreasing order was Escherichia coli (42.2%), Klebsiella spp. (16.8%) and Staphylococcus aureus (13.9%). Acinetobacter spp. were the only pathogens to decrease significantly (7% reduction; P = 0.033). The most common resistant pathogens were extended-spectrum cephalosporin-resistant E. coli (37.1%), extended-spectrum cephalosporin-resistant Klebsiella (27.8%), carbapenem-non-susceptible Acinetobacter spp. (19.5%), carbapenem-non-susceptible Pseudomonas aeruginosa (19.2%) and methicillin-resistant S. aureus (18.6%).
CONCLUSION: National collaboration is required by prompt feedback to local authorities to tackle regional differences in AMR. This can help plan timely containment interventions to stop and contain microbial threats and swiftly assess their impact.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antibacterial agents; Antimicrobial resistance; Isolates; Multidrug resistance; Pathogens; Saudi Arabia

Year:  2021        PMID: 33762211     DOI: 10.1016/j.jgar.2021.03.009

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  4 in total

1.  Prevalence of multidrug-resistant strains in device associated nosocomial infection and their in vitro killing by nanocomposites.

Authors:  Shahbaz Aman; Divya Mittal; Shalini Shriwastav; Hardeep Singh Tuli; Shubham Chauhan; Pardeep Singh; Sheetal Sharma; Reena V Saini; Narinder Kaur; Adesh K Saini
Journal:  Ann Med Surg (Lond)       Date:  2022-05-03

2.  Prevalence of Multidrug-Resistant Pathogens Causing Bloodstream Infections in an Intensive Care Unit.

Authors:  Andreea-Loredana Golli; Oana Mariana Cristea; Adina-Dorina Glodeanu; Ovidiu Zlatian; Andrei Theodor Balasoiu; Mihaela Ionescu; Simona Popa
Journal:  Infect Drug Resist       Date:  2022-10-17       Impact factor: 4.177

3.  Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review.

Authors:  Saad Alhumaid; Abbas Al Mutair; Zainab Al Alawi; Murtadha Alsuliman; Gasmelseed Y Ahmed; Ali A Rabaan; Jaffar A Al-Tawfiq; Awad Al-Omari
Journal:  Antimicrob Resist Infect Control       Date:  2021-06-03       Impact factor: 4.887

4.  Restriction on antimicrobial dispensing without prescription on a national level: Impact on the overall antimicrobial utilization in the community pharmacies in Saudi Arabia.

Authors:  Ahmed Hamdan Al-Jedai; Yasser Almogbel; Khalid Eljaaly; Nasser M Alqahtani; Hajer Yousef Almudaiheem; Nancy Awad; Dema Abdulrahman Alissa; Abdullah Assiri; Tareef Alaama
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.